Literature DB >> 22098676

Comparison of multiple estimates of efficacy for influenza vaccine.

Mark Loeb1, Margaret L Russell, Kevin Fonseca, Richard Webby, Stephen D Walter.   

Abstract

Influenza vaccine trials typically report vaccine efficacy for infection-confirmed symptomatic illness. Data on indirect vaccine efficacy for susceptibility, the degree of vaccine protection to susceptibles, or indirect vaccine efficacy for illness given infection, are sparse. Using inactivated influenza vaccine randomized trial data, we calculated indirect vaccine efficacy for susceptibility of 20% [95% CI 9-30] and indirect vaccine efficacy for illness among infected persons 12% [95% CI 2-22], values inferior to a direct vaccine efficacy for infection-confirmed symptomatic illness of 55% [95% CI -21 to 84] and an indirect effect of 61% [95% CI 8-83]. Such data reveal variance in protective efficacy of the vaccine for multi-dimensional direct and indirect efficacy measures.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098676     DOI: 10.1016/j.vaccine.2011.10.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

Authors:  Yoshikazu Honda-Okubo; Fadi Saade; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.